Diy13/iStock via Getty Images
Shares of Traws Pharma (NASDAQ:TRAW) shot up 24% in post-market trading Friday on encouraging results from a Phase 1 study of the company’s drug Tivoxavir Marboxil in the treatment of H5N1 avian flu.
The study showed a single dose of